By

Admin
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma (MM) in Israel. The findings were reported in Leukemia Research. The study was conducted using databases from Maccabi Healthcare Services, a nationwide health plan in Israel that accounts for a quarter of the country’s population. The prevalence of MM was determined...
Continue Reading
Blood cancer is actually a term applied to three different types of cancer – leukemia, lymphoma and myeloma. For centuries, these cancers had virtually no possibility of survival. Even as recently as the 1960s, the five-year survival rate for leukemia was 14%. By 2010, it had increased to 61%. Similar gains have been made in the survival...
Continue Reading
Patients with multiple myeloma are at risk of developing thrombosis (blood clots) that are associated with some newer treatments, according to two myeloma experts. Therefore, researchers from Fred Hutchinson Cancer Research Center, the University of Washington and Seattle Cancer Alliance, examined if they could identify risk factors for patients to determine who would most likely...
Continue Reading
Myeloma is a complicated cancer type that can be tough to find a treatment option for which patients will respond to. However, in the past several months therapeutic options for patients with relapsed/refractory multiple myeloma have taken major steps forward. This in part due to new data from multiple trials including the phase III COLUMBA...
Continue Reading
The Government has today unveiled plans to establish a national cancer agency, which will be led directly by experts of the deadly disease, and a $60 million injection into Pharmac. Until today, decisions about how to tackle New Zealand’s cancer “crisis” came from bureaucrats within the Ministry of Health. By December 1, the Government has...
Continue Reading
According to findings from a study published in Cancer on the utilization of specific supportive care measures in older patients with multiple myeloma, only approximately two-thirds of patients received guideline-concordant administration of a bone-modifying agent. The course of treatment for patients with multiple myeloma is typically characterized by the administration of multiple lines of therapy associated with periods...
Continue Reading
Renal impairment (RI) is a poor prognostic factor in patients with multiple myeloma (MM). Despite improvements in survival with the introduction of novel therapies in recent years, RI remains one of the most common complications with an incidence of 20% to 50% at diagnosis, and approximately 5% to 10% of MM patients are dialysis-dependent.1-3 The...
Continue Reading
A Phase II study of a GlaxoSmithKline drug to treat the blood cancer multiple myeloma has been successful, the company said Friday. The London-based drugmaker said it had positive headline results from the DREAMM-2 study of GSK2857916 (belantamab mafodotin), an antibody-drug conjugate that targets the antigen BCMA. It did not provide details of the data, but said...
Continue Reading
A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with relapsed or refractory multiple myeloma, according to results of a single-center, single-arm phase 2 clinical trial published in The Lancet Haematology. The dual CAR T-cell combination resulted in a 95% response rate, with 43% of patients achieving...
Continue Reading
1 2 3 4 5 20

Floor 7, 90 The Terrace
Wellington Central
New Zealand